SCHEMBL4066225

SCHEMBL4066225

OCc1ccccc1Sc1ccc2cc(Cl)ccc2n1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SLC6A4 P31645 5/20 0.47
▸ APOBEC3G Q9HC16 1/20 0.40
▸ SLC6A2 P23975 2/20 0.36
▸ SLC6A3 Q01959 2/20 0.36
▸ TDP1 Q9NUW8 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ ITGB2 P05107 1/20 0.35
▸ ICAM1 P05362 1/20 0.35
▸ ITGAL P20701 1/20 0.35
▸ CYP2A6 P11509 1/20 0.35
▸ CTSD P07339 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ NHERF1 O14745 1/20 0.34
▸ PRNP P04156 1/20 0.34
▸ KCNK2 O95069 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4439230 0.78 SLC6A4 (0.61) SLC6A4APOBEC3GSLC6A2SLC6A3ALDH1A1
SCHEMBL4437763 0.75 SLC6A4 (0.75) SLC6A4APOBEC3GSLC6A2SLC6A3ALDH1A1
SCHEMBL1191610 0.70 SLC6A4 (0.63) SLC6A4APOBEC3GSLC6A2SLC6A3KDM4E
SCHEMBL9541450 0.69 SLC6A4 (0.82) SLC6A4SLC6A2SLC6A3TDP1KDM4E
SCHEMBL4075582 0.68 CYP2D6 (0.37) TDP1CYP2A6NHERF1PRNP
SCHEMBL8559109 0.68 HTR3A (0.37) TP53MAPTCYP2A6CTSD
SCHEMBL8559644 0.68 MAPT (0.53) KDM4ETP53MAPTCTSDKMT2A
SCHEMBL4442278 0.68 APOBEC3G (0.73) SLC6A4APOBEC3GSLC6A2SLC6A3ALDH1A1
SCHEMBL7808149 0.68 HDAC1 (0.49) TDP1ALDH1A1CYP2A6KMT2A
SCHEMBL9541406 0.68 SLC6A4 (0.92) SLC6A4SLC6A2SLC6A3TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592456-B2 Arylsulfonylnaphthalene derivatives as 5HT2A antagonists MERCK SHARP & DOHME LIMITED (GB) 2009-09-22 — — US disclosed
EP-1824817-B1 ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS MERCK SHARP & DOHME (GB) 2009-02-04 — — EP disclosed
US-20070281952-A1 Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists MERCK SHARPE & DOHME LIMITED (GB) 2007-12-06 — — US disclosed
EP-1824817-A1 ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2007-08-29 — — EP disclosed
WO-2006059149-A1 ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2006-06-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281952-A1 Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists HTR2A, HTR2C, HTR1A SLC6A4 19/4885APOBEC3G 4608/4885SLC6A2 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback